Latest News
Chiesi Group, a European pharmaceutical company, has signed through its UK affiliate Chiesi Ltd a definitive agreement with Sunstone Capital to acquire Zymenex, a biopharmaceutical group focused on research and development of biologic therapeutics for the treatment of rare and life threatening genetic diseases.
Terms of the transaction have not been disclosed.
The acquisition of Zymenex includes Lamazym, a phase III recombinant enzyme indicated for use to treat patients suffering from alpha-Mannosidosis, as well as other early stage compounds.
Zymenex R&D capabilities will establish a research and development position for Chiesi in the recombinant biologics market for
Aquiline Capital Partners has made an investment, through affiliates, in Tourmalet Advisors, an alternative investment manager based in Fairfield, Connecticut.
Tourmalet, led by chief executive officer Michael Corasaniti, was founded in October 2009 and has a track record of managing, investing, structuring and trading distressed residential mortgage assets. The firm’s objective is to generate superior risk adjusted returns through the purchase, servicing and liquidation of distressed whole loans.
“We have known Mike Corasaniti and his team at Tourmalet for a number of years and have been impressed with their expertise and approach to investing in the residential mortgage
By Alexander Lüring (pictured), partner of the competence centre "Private Equity" at Homburg & Partner, and Sebastian Elbel, Consultant at Homburg & Partner – Many medium-sized businesses are faced with constant cost pressure. The price of copper has increased an average of 8 percent annually over the past three years. Rapidly increasing oil prices have skyrocketed by up to 58 percent over the past three years.
According to regular surveys on recent trends and challenges in classical B2B branches conducted by Germany-based management consultancy, Homburg & Partner, (“Building material monitor”, “Chemicals monitor”, “Logistics explorer” or “Mechanical engineering monitor”), the increasing
Qualcomm is to sell Omnitracs, its North and Latin American transportation and logistics business, to Vista Equity Partners, a US-based private equity firm.
Subject to the terms and conditions of the definitive agreement, Vista will purchase Omnitracs for USD800m in cash.
"In the late 1980s, Qualcomm pioneered the use of commercial vehicle telematics with the introduction of the first mobile information system for transportation and logistics. As one of Qualcomm’s earliest businesses, Omintracs has maintained a leadership position within the industry for 25 years. Today, the opportunity for fleet management and telematics is evolving rapidly, and we believe
Avinash Vazirani, manager of the Jupiter India Fund says Indian politics, a rudderless central bank and US tapering fears are all playing their part in driving down the Indian rupee. India’s long-term economic growth prospects however should, in his view, continue to reward the patient investor…
Tracking the latest slump in the Indian rupee against the world’s major currencies, we have been struck by how reluctant the Reserve Bank of India (RBI) has been to intervene directly in the markets to support the currency. There was a time when the RBI was much less shy about coming forward. At the
Keating Capital, a pre-IPO investor and business development company, has made an additional USD1m convertible note investment in SilkRoad, an existing portfolio company.
Keating Capital’s investment is part of a USD16m growth financing round completed by SilkRoad.
Other participants in the financing include Foundation Capital, Intel Capital, Azure Capital Partners and Crosslink Ventures.
SilkRoad intends to use the new funding to fuel ongoing product innovation across SilkRoad’s Life Suite talent management software to support company growth.
Chicago-based SilkRoad is a provider of cloud-based human capital management (HCM) solutions to small- and medium-sized businesses (SMBs). SilkRoad’s Life
Private equity firm Thoma Bravo has completed its acquisition of Keynote Systems, a provider of internet and mobile cloud testing and monitoring, for USD20 per share or approximately USD395m.
With the transaction completed, Keynote’s stock will cease trading on the Nasdaq under the ticker symbol KEYN.
Keynote will remain headquartered in San Mateo, California. In addition, retiring chief executive Umang Gupta will transition the CEO role to software and technology industry veteran Jennifer Tejada.
“Jennifer brings a passion for innovation and unparalleled experience to hit the ground running with the tremendous platform that Umang and the Keynote team
Singapore-based private equity firm KV Asia Capital has held the final closing of its first fund, KV Asia Capital Fund I, on USD263m.
KV Asia Capital attracted commitments from a diverse range of global institutions, including pension funds, endowments, financial institutions, fund of funds and family offices.
“We are pleased with the positive response to our offering and the recognition we have received. We have a high calibre team and are now eager to execute on our commitment to help mid-sized companies grow through operational value add and cross border activity," says Karam Butalia, executive chairman at KV Asia
TagMan, a tag management system, marketing data and marketing attribution provider, has received USD5m in new funding.
Existing investors Greycroft Partners and iNovia Capital led the financing, and Silicon Valley Bank also injected capital.
TagMan plans to use the awarded funds to ramp up growth of its 300-strong global partnership programme STREAM, which was launched in October 2012 and to support the growth of the company’s customer base globally. STREAM offers its certified partners streamlined tag implementations, reliable real-time, tag enabled data collection and clean, cross-channel marketing data from an independent source. The programme is open to best-in-class application
MicuRx Pharmaceuticals, a privately-held biopharmaceutical company developing next-generation antibiotics, has raised USD25m in series B financing.
Led by BVCF, a private equity and growth fund specialising in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures.
Proceeds from the series B financing will be used to fund the US development of MRX-I, a novel oral oxazolidinone antibiotic targeting infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Weixin Xu and Davis Yang of BVCF will join the MicuRx board of directors.
"We invest in
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
